Publication:
Insulin resistance, obesity, and lipotoxicity

dc.contributor.departmentKUH (Koç University Hospital)
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorDemir, Selin Çakmak
dc.contributor.kuauthorDereli, Dilek Yazıcı
dc.contributor.kuauthorSezer, Havva
dc.contributor.schoolcollegeinstituteKUH (KOÇ UNIVERSITY HOSPITAL)
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-03-06T20:57:19Z
dc.date.issued2024
dc.description.abstractLipotoxicity, originally used to describe the destructive effects of excess fat accumulation on glucose metabolism, causes functional impairments in several metabolic pathways, both in adipose tissue and peripheral organs, like liver, heart, pancreas, and muscle. Ectopic lipid accumulation in the kidneys, liver, and heart has important clinical counterparts like diabetic nephropathy in type 2 diabetes mellitus, obesity-related glomerulopathy, nonalcoholic fatty liver disease, and cardiomyopathy. Insulin resistance due to lipotoxicity indirectly lead to reproductive system disorders, like polycystic ovary syndrome. Lipotoxicity has roles in insulin resistance and pancreatic beta-cell dysfunction. Increased circulating levels of lipids and the metabolic alterations in fatty acid utilization and intracellular signaling have been related to insulin resistance in muscle and liver. Different pathways, like novel protein kinase c pathways and the JNK-1 pathway, are involved as the mechanisms of how lipotoxicity leads to insulin resistance in nonadipose tissue organs, such as liver and muscle. Mitochondrial dysfunction plays a role in the pathogenesis of insulin resistance. Endoplasmic reticulum stress, through mainly increased oxidative stress, also plays an important role in the etiology of insulin resistance, especially seen in non-alcoholic fatty liver disease. Visceral adiposity and insulin resistance both increase the cardiometabolic risk, and lipotoxicity seems to play a crucial role in the pathophysiology of these associations. © The Author(s), under exclusive license to Springer Nature Switzerland AG 2024.
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.identifier.doi10.1007/978-3-031-63657-8_14
dc.identifier.issn0065-2598
dc.identifier.quartileN/A
dc.identifier.scopus2-s2.0-85204417786
dc.identifier.urihttps://doi.org/10.1007/978-3-031-63657-8_14
dc.identifier.urihttps://hdl.handle.net/20.500.14288/27198
dc.keywordsCardiomyopathy
dc.keywordsCeramides
dc.keywordsCytokines
dc.keywordsDiabetic nephropathy
dc.keywordsDiacylglycerol
dc.keywordsEndoplasmic reticulum stress
dc.keywordsFatty acids
dc.keywordsInsulin resistance
dc.keywordsLipotoxicity
dc.keywordsNonalcoholic fatty liver disease
dc.keywordsObesity
dc.keywordsPolycystic ovary syndrome
dc.keywordsType 2 diabetes mellitus
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofAdvances in Experimental Medicine and Biology
dc.subjectMedicine
dc.titleInsulin resistance, obesity, and lipotoxicity
dc.typeBook Chapter
dspace.entity.typePublication
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit1KUH (KOÇ UNIVERSITY HOSPITAL)
local.publication.orgunit2KUH (Koç University Hospital)
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryf91d21f0-6b13-46ce-939a-db68e4c8d2ab
relation.isParentOrgUnitOfPublication055775c9-9efe-43ec-814f-f6d771fa6dee
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery055775c9-9efe-43ec-814f-f6d771fa6dee

Files